Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
5.04
-0.01 (-0.20%)
Feb 4, 2025, 4:00 PM EST - Market closed
Molecular Partners AG Revenue
Molecular Partners AG had revenue of 681.00K CHF in the quarter ending September 30, 2024, a decrease of -73.20%. This brings the company's revenue in the last twelve months to 6.00M, down -31.03% year-over-year. In the year 2023, Molecular Partners AG had annual revenue of 7.04M, down -96.29%.
Revenue (ttm)
6.00M CHF
Revenue Growth
-31.03%
P/S Ratio
n/a
Revenue / Employee
35,833 CHF
Employees
168
Market Cap
181.79M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.04M | -182.56M | -96.29% |
Dec 31, 2022 | 189.60M | 179.85M | 1,843.82% |
Dec 31, 2021 | 9.75M | 410.00K | 4.39% |
Dec 31, 2020 | 9.34M | -11.04M | -54.16% |
Dec 31, 2019 | 20.38M | 10.03M | 96.84% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 56.33B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
MOLN News
- 20 days ago - Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical Programs - Seeking Alpha
- 23 days ago - Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 23 days ago - Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer - GlobeNewsWire
- 7 weeks ago - Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January - GlobeNewsWire
- 2 months ago - Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024 - GlobeNewsWire
- 3 months ago - Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024 - GlobeNewsWire
- 3 months ago - Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going - GlobeNewsWire
- 3 months ago - Molecular Partners Announces Pricing of $20 Million Underwritten Offering - GlobeNewsWire